✦ LIBER ✦

PDB56 PHARMACOECONOMIC CONSEQUENCES OF LOSARTAN THERAPY IN PATIENTS UNDERGOING DIABETIC END-STAGE RENAL DISEASE IN EU AND USA

✍ Scribed by A Citarella; S de Portu; S Cammarota; E Menditto; LG Mantovani

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PDB29 PHARMACOECONOMIC CONSEQUENCES OF L

✍ A Citarella; LG Mantovani; S Cammarota; E Menditto; S Riegler; S De Portu 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB

Comparison of renal transplantation and

✍ Raja B. Khauli; Andrew C. Novick; Donald R. Steinmuller; Caroline Buszta; Satoru 📂 Article 📅 1986 🏛 Elsevier Science 🌐 English ⚖ 511 KB

The Prevalence and Types of Cardiovascul

✍ Bozbas, H.; Altin, C.; Karacaglar, E.; Kanyilmaz, S.; Yildirir, A.; Muderrisoglu 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 192 KB

PUK8 COST EFFECTIVENESS OF ICODEXTRINE-B

✍ F Garcia-Contreras; P Constantino-Casas; I Prieto-Arenas; D Amato; JC Blackburn; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

Losartan and the United States costs of

✍ Alexander, Charles M.; Lyle, Paulette A.; Keane, William F.; Carides, George W.; 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 78 KB

Inflammatory markers and progression of

✍ Ana Paula Silva; Alexandre Baptista; Pedro Leão Neves 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 56 KB